Needle-free Delivery as a Drug Development and Lifecycle Strategy
Designed for Sustainable Self-Administration
•Enables patient-centric self-injection without changing drug formulation
•Supports long-term treatment adherence in chronic and preventive therapies
•Suitable for home-use scenarios under established human factors frameworks
Aligned with Clinical and Risk Management Considerations
•Eliminates needle-related handling and disposal risks
•Reduces variability associated with needle insertion and withdrawal
•Designed to minimize localized tissue stress under controlled delivery profiles
A Differentiation Layer Without Reformulation
•Enables product differentiation at the device and delivery level
•Preserves existing drug substance and drug product strategy
•Supports lifecycle extension and market-specific variant positioning
Drug-Specific Delivery Evidence
Published data supporting needle-free delivery across drug categories:
•Acute therapies → rapid dispersion profiles supporting fast onset
•Sustained-release formulations → uniform distribution reducing local stress
•Nucleic acid drugs (mRNA) → micro-jet delivery enhancing cellular uptake
Explore Scientific Publications
Independent IP Portfolio Supporting Secure Collaboration
With an independent patent portfolio covering core mechanisms, device architecture, and key components, our needle-free technology provides a stable IP foundation for licensing, co-development, and long-term collaboration.
How to Engage with Quinovare
How to Engage with Quinovare
A structured entry path for pharmaceutical and biotech collaboration.
Typical engagement pathways include:
• Device evaluation and technical discussion under NDA
• Platform adaptation for specific drug formulations and delivery needs therapies
• Co-development of combination products for global registration
• Licensing or regional collaboration based on defined scopes
NEach engagement follows a staged process aligned with pharmaceutical development and regulatory requirements.









